TB epidemic looms large in era of declining R&D funding
October 2016 delivered two sobering wake-up calls: The tuberculosis (TB) epidemic is larger than many realized, and TB R&D has has fallen to its lowest level in seven years.
Sign up to receive news and updates from GHTC.
TB/HIV Project Officer
Total of 4 blog posts
October 2016 delivered two sobering wake-up calls: The tuberculosis (TB) epidemic is larger than many realized, and TB R&D has has fallen to its lowest level in seven years.
In this guest post, Mike Frick, TB/HIV project officer at the Treatment Action Group (TAG), reflects on activist calls for greater investment in tuberculosis (TB) research and development (R&D) at the 46th Union World Conference on Lung Health and the stagnation of global TB R&D funding at a time of growing drug resistance.
In this guest post, Mike Watson Frick—TB/HIV program officer at Treatment Action Group (TAG)—writes about the state of tuberculosis (TB) research funding and civil society actions that took place at the recent Union World Conference on Lung Health in Barcelona, Spain.
Each year since 2006, TAG has tracked spending on research and development (R&D) for new diagnostics, drugs, and vaccines to improve TB treatment and prevention.